A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.

(H.R.696/S.506) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP) generally (in the context of deficit reduction); Medicare Program Part B Drug Payment Model.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Average Sales Price (H.R. 696, S. 506); PPACA Implementation (PL 111-148); Sustainable Growth Rate (H.R. 2); Centers for Medicare and Medicaid Services (AMP and NADAC); Part B Demonstration Proposal

Client expense: $268,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Average Sales Price (H.R. 696, S. 506) PPACA Implementation (PL 111-148) SGR (H.R. 2) Centers For Medicare and Medicaid Services (AMP and NADAC) Part B demonstration (H.R. 5122)

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Pharmaceutical distribution management ASP reimbursement policy under Medicare Part B S.506/H.R.696- A bill to exclude prompt pay discount from calculation of ASP Part B drug payment demonstration

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934; S. 3211). Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506). Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, and Medicare reimbursement for cancer care. General discussion on the CMS/CMMI Medicare Part B Payment Model to cut Medicare Part B drug reimbursement. Specific legislation to stop the Medicare Part B Drug Payment Model (H.R. 5122). Topics related to pharmaceutical benefit managers (PBMs)

Client expense: $112,500 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

The Medicare Patient Access to Cancer Treatment Act (H.R. 2895) The Preserve Community Care Cancer Act (H.R. 696 / S. 506)

Client expense: Not reported · Firm income: $40,500

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative (LCA) policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015 H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare Part B Prescription Drug Models

Client expense: $270,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.

Client expense: $310,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- S. 506/H.R. 696(Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologics under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP), generally including CMS' proposed Part B Drug payment demonstration rule. Sequestration cuts to cancer care. - H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934; S. 3211). Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506). Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, and Medicare reimbursement for cancer care. General discussion on the CMS/CMMI Medicare Part B Payment Model to cut Medicare Part B drug reimbursement. Specific legislation to stop the Medicare Part B Drug Payment Model (H.R. 5122).

Client expense: $174,500 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

(H.R. 696/S. 506) Medicare Prompt Pay Discount Exclusion,legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Legislation to exclude cancer drugs from sequestration cuts. HR471/S483 Ensuring Patient Access and Effective Drug Enforcement Act of 2015; Medicare Program Part B Drug Payment Model.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

(H.R.696/S.506) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP) generally (in the context of deficit reduction); Medicare Program Part B Drug Payment Model.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Average Sales Price (H.R. 696, S. 506) PPACA Implementation (PL 111-148) SGR (H.R. 2) Centers For Medicare and Medicaid Services (AMP and NADAC) Part B demonstration (H.R. 5122)

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Average Sales Price (H.R. 696, S. 506); PPACA Implementation (PL 111-148); Sustainable Growth Rate (H.R. 2); Centers for Medicare and Medicaid Services (AMP and NADAC); Part B Demonstration Proposal

Client expense: $267,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 696; S. 506

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmaceutical distribution management ASP reimbursement policy under Medicare Part B S.506/H.R.696- A bill to exclude prompt pay discount from calculation of ASP Part B drug payment demonstration

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- Medicare Patient Access to Cancer Treatment Act (H.R. 2895) - Prompt pay discount legislation, (HR 696 / S 506) - H.R. 1416 The Cancer Patient Protection Act of 2015 - site neutrality for ambulatory oncology services - Oppose proposed Medicare Part B drug payment demonstration (no specific bill)

Client expense: Not reported · Firm income: $40,500

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- Medicare Patient Access to Cancer Treatment Act (H.R. 2895) - Prompt pay discount legislation, (HR 696 / S 506) - H.R. 1416 The Cancer Patient Protection Act of 2015 - site neutrality for ambulatory oncology services

Client expense: Not reported · Firm income: $40,500

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative (LCA) policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015 H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare Part B Prescription Drug Models

Client expense: $280,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

S. 506/H.R. 696(Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologics under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP), generally including CMS' proposed Part B Drug payment demonstration rule. Sequestration cuts to cancer care. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

(H.R. 696/S. 506) Medicare Prompt Pay Discount Exclusion,legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Legislation to exclude cancer drugs from sequestration cuts. HR471/S483 Ensuring Patient Access and Effective Drug Enforcement Act of 2015; Medicare Program Part B Drug Payment Model.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

(H.R.696/S.506) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP) generally (in the context of deficit reduction); Medicare Program Part B Drug Payment Model.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 696; S. 506

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Average Sales Price (H.R. 696, S. 506) PPACA Implementation (PL 111-148) SGR (H.R. 2) Centers For Medicare and Medicaid Services (AMP and NADAC) Part B demonstration (H.R. 5122)

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.

Client expense: $300,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmaceutical distribution management ASP reimbursement policy under Medicare Part B S.506/H.R.696- A bill to exclude prompt pay discount from calculation of ASP Part B drug payment demonstration

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Average Sales Price (H.R. 696, S. 506); PPACA Implementation (PL 111-148); Sustainable Growth Rate (H.R. 2); Centers for Medicare and Medicaid Services (AMP and NADAC); Part B Demonstration Proposal

Client expense: $306,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934) and possible Senate companion bill. Legislation to stop CMS from applying the sequester cut to Medicare Part B drugs (H.R. 1416). Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506). Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, and Medicare reimbursement for cancer care. CMS/CMMI Medicare Part B Payment Model to cut Medicare Part B drug reimbursement.

Client expense: $186,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934) and possible Senate companion bill. Legislation to stop CMS from applying the sequester cut to Medicare Part B drugs (H.R. 1416). Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506). Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, Medicare 14-day rule, and Medicare reimbursement for cancer care. CMS/CMMI Medicare Part B Payment Model to cut Medicare Part B drug reimbursement.

Client expense: $92,700 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 506/H.R. 696(Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologics under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP), generally including CMS' proposed Part B Drug payment demonstration rule. Sequestration cuts to cancer care. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative (LCA) policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015

Client expense: $290,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

(H.R. 696/S. 506) Medicare Prompt Pay Discount Exclusion,legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Legislation to exclude cancer drugs from sequestration cuts. HR471/S483 Ensuring Patient Access and Effective Drug Enforcement Act of 2015.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

(H.R.696/S.506) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP) generally (in the context of deficit reduction).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 696; S. 506

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.

Client expense: $370,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Average Sales Price (H.R. 696, S. 506) PPACA Implementation (PL 111-148) SGR (H.R. 2) Centers For Medicare and Medicaid Services (AMP and NADAC) Part B demonstration

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Pharmaceutical distribution management ASP reimbursement policy under Medicare Part B S.506/H.R.696- A bill to exclude prompt pay discount from calculation of ASP

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Average Sales Price (H.R. 696, S. 506); PPACA Implementation (PL 111-148); Sustainable Growth Rate (H.R. 2); Centers for Medicare and Medicaid Services (AMP and NADAC); Part B Demonstration Proposal

Client expense: $314,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 506/H.R. 696(Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Sequestration cuts to cancer care. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015

Client expense: $260,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 696; S. 506

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934) Legislation to stop CMS from applying the sequester cut to Medicare Part B drugs (H.R. 1416). Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506). Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, Medicare 14-day rule, and Medicare reimbursement for cancer care.

Client expense: $85,800 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts.

Client expense: $820,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

(H.R. 696/S. 506) Medicare Prompt Pay Discount Exclusion,legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Legislation to exclude cancer drugs from sequestration cuts. HR471/S483 Ensuring Patient Access and Effective Drug Enforcement Act of 2015.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

(H.R.696/S.506) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP) generally (in the context of deficit reduction).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE